# Medline Inc.: overview

MDLN · Nasdaq · CIK 2046386 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mdln.md) · [Financials](/companies/mdln/financials.md) · [Filings](/companies/mdln/filings.md) · [Insiders](/companies/mdln/insiders.md)

Latest reported revenue: [$7.68bn](/filings/0002046386-26-000051.md) for Q2 FY2026, three months to 2026-06-27, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0002046386-26-000051).

## Last eight quarters

| Line item | Unit | period not labelled (2025-03-29) | period not labelled (2025-06-28) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [6,644](/filings/0002046386-26-000026.md) | [6,886](/filings/0002046386-26-000051.md) | [7,352](/filings/0002046386-26-000026.md) | [7,685](/filings/0002046386-26-000051.md) |
| Gross margin | % | [27.5%](/filings/0002046386-26-000026.md) | [27.7%](/filings/0002046386-26-000051.md) | [25.0%](/filings/0002046386-26-000026.md) | [28.8%](/filings/0002046386-26-000051.md) |
| Operating margin | % | [8.6%](/filings/0002046386-26-000026.md) | [9.3%](/filings/0002046386-26-000051.md) | [5.7%](/filings/0002046386-26-000026.md) | [5.1%](/filings/0002046386-26-000051.md) |
| Net margin | % | [4.8%](/filings/0002046386-26-000051.md) | [4.8%](/filings/0002046386-26-000051.md) | [3.3%](/filings/0002046386-26-000051.md) | [1.8%](/filings/0002046386-26-000051.md) |
| Diluted EPS | $ per share | not reported | not reported | [0.16](/filings/0002046386-26-000026.md) | [0.07](/filings/0002046386-26-000051.md) |
| Free cash flow | $m | [584](/filings/0002046386-26-000026.md) | [87.0 d](/filings/0002046386-26-000051.md) | [316](/filings/0002046386-26-000026.md) | [604 d](/filings/0002046386-26-000051.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Net income: us-gaap:ProfitLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-12-31) | FY (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $bn | [23.2](/filings/0002046386-26-000009.md) | [25.5](/filings/0002046386-26-000009.md) | [28.4](/filings/0002046386-26-000009.md) |
| Gross margin | % | [25.3%](/filings/0002046386-26-000009.md) | [27.3%](/filings/0002046386-26-000009.md) | [26.4%](/filings/0002046386-26-000009.md) |
| Operating margin | % | [5.4%](/filings/0002046386-26-000009.md) | [8.4%](/filings/0002046386-26-000009.md) | [7.8%](/filings/0002046386-26-000009.md) |
| Net margin | % | [1.0%](/filings/0002046386-26-000009.md) | [4.6%](/filings/0002046386-26-000009.md) | [4.1%](/filings/0002046386-26-000009.md) |
| Diluted EPS | $ per share | not reported | not reported | [(0.01)](/filings/0002046386-26-000009.md) |
| Free cash flow | $bn | [1.4](/filings/0002046386-26-000009.md) | [1.4](/filings/0002046386-26-000009.md) | [1.3](/filings/0002046386-26-000009.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:Revenues; Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mdln/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-05-28 | [BCP 8 Holdings Mozart Manager L.L.C.](/insiders/2094484.md) | 10% owner | Sale (S) | 1,489,924 | $36.5375 | $54.4m | [Form 4](/filings/0001193125-26-251451.md) |
| 2026-05-28 | [BCP 8 Holdings Mozart Manager L.L.C.](/insiders/2094484.md) | 10% owner | Sale (S) | 2,256,800 | $36.5375 | $82.5m | [Form 4](/filings/0001193125-26-251451.md) |
| 2026-05-28 | [BCP 8 Holdings Mozart Manager L.L.C.](/insiders/2094484.md) | 10% owner | Sale (S) | 9,858,774 | $36.5375 | $360.2m | [Form 4](/filings/0001193125-26-251451.md) |
| 2026-05-28 | [BCP 8 Holdings Mozart Manager L.L.C.](/insiders/2094484.md) | 10% owner | Sale (S) | 19,712,326 | $36.5375 | $720.2m | [Form 4](/filings/0001193125-26-251451.md) |
| 2026-03-10 | [BCP 8 Holdings Mozart Manager L.L.C.](/insiders/2094484.md) | 10% owner | Sale (S) | 1,245,544 | $40.508 | $50.5m | [Form 4](/filings/0001193125-26-104180.md) |
| 2026-03-10 | [BCP 8 Holdings Mozart Manager L.L.C.](/insiders/2094484.md) | 10% owner | Sale (S) | 1,886,636 | $40.508 | $76.4m | [Form 4](/filings/0001193125-26-104180.md) |
| 2026-03-10 | [BCP 8 Holdings Mozart Manager L.L.C.](/insiders/2094484.md) | 10% owner | Sale (S) | 8,241,723 | $40.508 | $333.9m | [Form 4](/filings/0001193125-26-104180.md) |
| 2026-03-10 | [BCP 8 Holdings Mozart Manager L.L.C.](/insiders/2094484.md) | 10% owner | Sale (S) | 16,479,083 | $40.508 | $667.5m | [Form 4](/filings/0001193125-26-104180.md) |
| 2025-12-18 | [Mozart Aggregator II LP](/insiders/2098582.md) | 10% owner | Sale (S) | 13,462,600 | $28.3683 | $381.9m | [Form 4](/filings/0001193125-25-328815.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Carlyle Group Inc.](/funds/1527166.md) | 2026-06-30 | $7.38bn | 187,083,713 |  | Unchanged |
| [H&F Corporate Investors X, Ltd.](/funds/1901930.md) | 2026-06-30 | $2.80bn | 70,874,326 |  | Reduced −15,599,171 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.85bn | 46,963,203 |  | Added +10,407,002 |
| [Capital Research Global Investors](/funds/1422848.md) | 2026-06-30 | $1.58bn | 39,963,790 |  | Added +16,802,120 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $1.51bn | 38,346,937 |  | Added +17,383,322 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.04bn | 26,393,587 |  | Added +9,469,927 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $852.1m | 21,605,662 |  | Added +5,902,759 |
| [LONE PINE CAPITAL LLC](/funds/1061165.md) | 2026-06-30 | $827.0m | 20,968,367 |  | Added +9,179,211 |
| [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $787.1m | 19,888,806 |  | Added +8,319,490 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $702.7m | 17,816,057 |  | Added +3,086,376 |

## Recent filings

[All 156 filings](/companies/mdln/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-21 | 16:17 ET | [8-K](/filings/0001104659-26-117844.md) | 7.01 Regulation FD disclosure | 0001104659-26-117844 |
| 2026-10-15 | 16:18 ET | [8-K](/filings/0001104659-26-116255.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-116255 |
| 2026-08-05 | 16:48 ET | [10-Q](/filings/0002046386-26-000051.md) | Quarterly report, period 2026-06-27 | 0002046386-26-000051 |
| 2026-08-05 | 07:34 ET | [8-K](/filings/0002046386-26-000049.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002046386-26-000049 |
| 2026-07-09 | 16:00 ET | [8-K](/filings/0001104659-26-082249.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-082249 |
| 2026-06-12 | 16:20 ET | [8-K](/filings/0002046386-26-000037.md) | 5.07 Shareholder vote results | 0002046386-26-000037 |
| 2026-06-02 | 08:06 ET | [8-K](/filings/0001193125-26-252557.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-252557 |
| 2026-05-20 | 07:01 ET | [S-1](/filings/0001193125-26-231691.md) | Registration statement | 0001193125-26-231691 |
| 2026-05-06 | 16:18 ET | [10-Q](/filings/0002046386-26-000026.md) | Quarterly report, period 2026-03-28 | 0002046386-26-000026 |
| 2026-05-06 | 07:35 ET | [8-K](/filings/0002046386-26-000022.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002046386-26-000022 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0002046386-26-000009.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-27, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d24216d5-df6e-4094-8ae0-664ed8af2704)

## About the filer

- CIK: 2046386
- Tickers: MDLN
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 15:07 ET. No prices; not investment advice.